{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:42:35Z","timestamp":1778496155277,"version":"3.51.4"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"DOI":"10.13039\/sphrjdddx9vm","name":"No funding was received for this systematic review.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/sphrjdddx9vm","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lamotrigine monotherapy is the first-line treatment for epilepsy in pregnant women. However, altered pharmacokinetics during pregnancy can lead to suboptimal drug levels and increased seizure risk. This systematic review aimed to evaluate current therapeutic drug monitoring (TDM) strategies for lamotrigine monotherapy in pregnant women with epilepsy and provide guidance for monitoring and dose adjustments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic search was performed using the Ovid-MEDLINE, Ovid-EMBASE, and Ovid-Cochrane Central Register of Controlled Trials databases. Studies were included if data on lamotrigine dosing, concentration, TDM strategies, efficacy, or safety were available.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eleven studies were analyzed, revealing heterogeneity in outcomes with selective reporting of TDM strategies; however, clear similarities were observed. Blood samples were collected every 1\u20133 months during pregnancy to maintain prepregnancy baseline drug levels. Lamotrigine's apparent and relative clearance increased across trimesters, particularly in the second and third trimesters, coinciding with a period of increased seizure frequency and required dose adjustments. Details on dose adjustments were limited. Some studies have proposed using the threshold of the ratio to the target concentration to predict increased seizure risk. No distinct association was observed between adverse newborn outcomes and lamotrigine dose or serum concentration. Few maternal adverse effects have been reported after delivery, confirming the necessity of empirical postpartum tapering.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Further studies are required to establish evidence-based standardized protocols encompassing all aspects of TDM. Early interventions, such as empirical dose increases during pregnancy and postpartum tapering, and routine monitoring from preconception to the postpartum period may enhance seizure control, reducing the risk of breakthrough seizures for the mother and unborn child.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001186","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T05:00:48Z","timestamp":1708146048000},"page":"181-194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Dose Monitoring of Lamotrigine Monotherapy in Pregnancy: Are Pregnant Women with Epilepsy Currently Optimally Managed? A Systematic Review"],"prefix":"10.1097","volume":"46","author":[{"given":"Yeonkyung","family":"Goo","sequence":"first","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marijn","family":"der Nederlanden","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Leiden University Medical Centre, Leiden University, Leiden, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bleasel","sequence":"additional","affiliation":[{"name":"Neurology Department, Westmead Hospital, Westmead, Australia;"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;"},{"name":"Westmead Hospital, Westmead, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-5036","authenticated-orcid":false,"given":"Hannah Yejin","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia;"},{"name":"Westmead Hospital, Westmead, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMoa2008663","article-title":"Changes in seizure frequency and antiepileptic therapy during pregnancy","volume":"383","author":"Pennell","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/jnnp.2003.029132","article-title":"The longer term outcome of children born to mothers with epilepsy","volume":"75","author":"Adab","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing: an observational study","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/jnnp-2017-317368","article-title":"Changing antiepilepsy drug-prescribing trends in women with epilepsy in the UK and Ireland and the impact on major congenital malformations","volume":"89","author":"Kinney","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2018.04.009","article-title":"Changes in antiepileptic drug-prescribing patterns in pregnant women with epilepsy","volume":"84","author":"Meador","year":"2018","journal-title":"Epilepsy Behav"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hernandez-Diaz","year":"2012","journal-title":"Neurology"},{"key":"R10-20250603","first-page":"271","article-title":"Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring","volume":"48","author":"Miskov","year":"2009","journal-title":"Acta Clin Croat"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007691-200502000-00004","article-title":"Cost-effectiveness of therapeutic drug monitoring: a systematic review","volume":"27","author":"Touw","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","article-title":"Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency","volume":"70","author":"Pennell","year":"2008","journal-title":"Neurology"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.seizure.2018.09.004","article-title":"Review on the relevance of therapeutic drug monitoring of levetiracetam","volume":"62","author":"Sourbron","year":"2018","journal-title":"Seizure"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/CPJ.0000000000000722","article-title":"Clinical utility of therapeutic drug monitoring of antiepileptic drugs: systematic review","volume":"10","author":"Al-Roubaie","year":"2020","journal-title":"Neurol Clin Pract"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: a systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2165\/00003495-200767180-00007","article-title":"Management of epilepsy during pregnancy","volume":"67","author":"Battino","year":"2007","journal-title":"Drugs"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1528-1167.2007.01471.x","article-title":"Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy","volume":"49","author":"Ohman","year":"2008","journal-title":"Epilepsia"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1528-1167.2007.01032.x","article-title":"Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation","volume":"48","author":"Tomson","year":"2007","journal-title":"Epilepsia"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2174\/1570159X19666210211150856","article-title":"Use of phenytoin, phenobarbital carbamazepine, levetiracetam lamotrigine and valproate in pregnancy and breastfeeding: risk of major malformations, dose-dependency, monotherapy vs polytherapy, pharmacokinetics and clinical Implications","volume":"19","author":"Kaplan","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0b013e3181a6b325","article-title":"Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society","volume":"73","author":"Harden","year":"2009","journal-title":"Neurology"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1212\/WNL.0000000000201348","article-title":"Association of levetiracetam concentration with seizure frequency in pregnant women with epilepsy","volume":"100","author":"Schelhaas","year":"2023","journal-title":"Neurology"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13760-018-0974-0","article-title":"The course of epilepsy and seizure control in pregnant women","volume":"118","author":"Shahla","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/j.1528-1167.2009.02166.x","article-title":"Seizure frequency in pregnant women treated with lamotrigine monotherapy","volume":"50","author":"Sabers","year":"2009","journal-title":"Epilepsia"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/epi.12302","article-title":"Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry","volume":"54","author":"Battino","year":"2013","journal-title":"Epilepsia"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamaneurol.2021.5487","article-title":"Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study","volume":"79","author":"Pennell","year":"2022","journal-title":"JAMA Neurol"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22230","article-title":"AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies","volume":"22","author":"Thangaratinam","year":"2018","journal-title":"Health Technol Assess"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"e01315","DOI":"10.1002\/brb3.1315","article-title":"Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy","volume":"9","author":"Ding","year":"2019","journal-title":"Brain Behav"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2013.06.026","article-title":"Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy","volume":"29","author":"Reisinger","year":"2013","journal-title":"Epilepsy Behav"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/epi4.12086","article-title":"Are doses of lamotrigine or levetiracetam adjusted during pregnancy?","volume":"3","author":"Richards","year":"2018","journal-title":"Epilepsia Open"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/cns.13796","article-title":"Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy","volume":"28","author":"Yin","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/01.WNL.0000133213.10244.FD","article-title":"Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study","volume":"63","author":"De Haan","year":"2004","journal-title":"Neurology"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/01.wnl.0000195888.51845.80","article-title":"Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cca.2014.06.002","article-title":"Advances in anti-epileptic drug testing","volume":"436","author":"Krasowski","year":"2014","journal-title":"Clin Chim Acta"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:08:36Z","timestamp":1748970516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001186","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"2023-08-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}